$BRSF Signs Memorandum of Understanding with $EHVVF to Map Brain Response

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company with two FDA-cleared products, has entered into a memorandum of understanding (“MoU”) with Ehave, Inc. (OTC: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors. The agreement calls for the two companies to work together to map brain response to psychedelics being administered as a treatment for chronic pain, depressions (both major and persistent), post-traumatic stress disorder, bipolar disorder, general anxiety, ADHD and schizophrenia. The two companies will also collaborate in the development of neural net algorithms for the mental-health sector. BRSF’s e-tattoo technology will be used to provide continuous monitoring in the studies. According to the announcement, the MoU calls for Ehave to integrate Brain Scientific’s NeuroCap and NeuroEEG to obtain data from patients in real time; Ehave may also use the two devices in clinical settings with Ehave’s partner healthcare providers in order to gather data about the electrophysiological changes in brain pre-, mid- and post-psychedelic drug administration. Initial plans indicate the collection research could start in Australia and then be implemented in other areas. The research and data will be jointly owned by both Ehave and Brain Scientific. “Our current EEG device is about the size of a stamp,” said Brain Scientific chairman Boris Goldstein in the press release. “By shrinking the technology, the system allows for continuous measurement during a person’s normal activities, while providing a non-intrusive way to monitor various disorders. We believe the future of EEG testing will be centered around the ability to gather more precise data through non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. By utilizing graphene, which has been called a ‘wonder material of the 21st century,’ Brain Scientific believes the size of the electrodes can be thinner than a human hair and will allow brain activity monitoring with minimal distraction from everyday life.”

To view the full press release, visit: https://ibn.fm/jwPjg

About Brain Scientific Inc.

Brain Scientific is a commercial-stage, health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information about this company, please visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.